Radiotherapy News and Research RSS Feed - Radiotherapy News and Research

Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).
New approach to fighting breast, thyroid cancers

New approach to fighting breast, thyroid cancers

A team of researchers from the University of Alberta has discovered a new approach to fighting breast and thyroid cancers by targeting an enzyme they say is the culprit for the "vicious cycle" of tumour growth, spread and resistance to treatment. [More]
Accelerated treatment regimen feasible for advanced NSCLC

Accelerated treatment regimen feasible for advanced NSCLC

A treatment strategy designed to minimise the effects of accelerated repopulation using hypofractionated radiotherapy with chemotherapy is feasible for patients with stage III non-small-cell lung cancer, according to UK researchers. [More]
Study finds significant disparities in lung cancer treatment based on race, insurance status

Study finds significant disparities in lung cancer treatment based on race, insurance status

African Americans, Hispanics, and those who receive care at a community hospital are all significantly less likely than other patients to receive treatment for early stage non-small cell lung cancer, according to a report in the Journal of Thoracic Oncology. [More]
Prostate cancer patients with hereditary BRCA mutations respond less well to conventional treatment

Prostate cancer patients with hereditary BRCA mutations respond less well to conventional treatment

Prostate cancer patients carrying inherited mutations in the BRCA genes respond less well to conventional treatment, including surgery and/or radiotherapy - and they also have a lower survival rate than those who are non-carriers of these genetic mutations. Data from the study, which has been published in the journal European Urology, points to the need for new clinical trials aimed at targeting these mutations in order to tailor treatment for these patients. [More]
Lobectomy outweighs sublobar resection for elderly early-stage NSCLC patients

Lobectomy outweighs sublobar resection for elderly early-stage NSCLC patients

Lobectomy may the best option for elderly patients with early-stage non-small-cell lung cancer who are able to undergo surgery, say researchers from the US. [More]
Postoperative radiation benefits N2 resected NSCLC patients

Postoperative radiation benefits N2 resected NSCLC patients

Patients with resected, margin-negative non-small-cell lung cancer with mediastinal node metastases derive significant benefit from postoperative radiotherapy, US researchers report. [More]
Novel medical-imaging technology helps make earlier treatment decisions for bowel cancer patients

Novel medical-imaging technology helps make earlier treatment decisions for bowel cancer patients

Technology developed at the University of Sussex helps hospitals make earlier and more accurate treatment decisions and survival assessments for patients with bowel cancer. [More]
Researchers develop genetic test to predict prostate cancer recurrence

Researchers develop genetic test to predict prostate cancer recurrence

Prostate cancer researchers have developed a genetic test to identify which men are at highest risk for their prostate cancer to come back after localized treatment with surgery or radiotherapy. [More]
New DNA-based test could better predict treatment outcomes for prostate cancer patients

New DNA-based test could better predict treatment outcomes for prostate cancer patients

Researchers at The Ontario Institute for Cancer Research and University Health Network, have identified a new DNA-based test that could be used to better predict how prostate cancer patients will respond to treatment and to prevent relapse. [More]
ViewRay's MRIdian system gets CE Mark approval

ViewRay's MRIdian system gets CE Mark approval

ViewRay, a privately held medical device company, announced today that its MRIdian (me-rid-i-an) system, the world's first and only MRI-guided radiation therapy system, has received CE Mark (Conformite Europeenne) approval. [More]
Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML). [More]
Scientists awarded grant to investigate new drug-based treatment for NF2

Scientists awarded grant to investigate new drug-based treatment for NF2

Scientists from Plymouth University Peninsula Schools of Medicine and Dentistry have been awarded a grant from young person's cancer charity The Laura Crane Youth Cancer Trust to investigate a new drug-based treatment for a multi-tumour brain and nervous system cancer which affects teenagers and young adults. [More]
Study sheds light on DCIS recurrence

Study sheds light on DCIS recurrence

Work by University of Manchester scientists has explored what allows some cases of Ductal Carcinoma in Situ (DCIS), a non-invasive form of breast cancer, to resist treatment and come back, as well as identifying a potential new target to improve the effectiveness of radiotherapy. [More]

AZD3965 drug inhibits growth of tumours in the lab

Manchester scientists have shown that a new drug inhibits the growth of tumours in the lab and that its effectiveness is improved by combining it with radiotherapy - suggesting a new approach that could be used in the clinic. [More]
Gefitinib drug boosts oesophageal cancer patients' survival by up to six months

Gefitinib drug boosts oesophageal cancer patients' survival by up to six months

Patients with a specific type of oesophageal cancer survived longer when they were given the latest lung cancer drug, according to trial results being presented at the National Cancer Research Institute (NCRI) Cancer Conference today (Wednesday). [More]
CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs. [More]
Data reveals sustained local control for early stage lung cancer patients who receive SBRT

Data reveals sustained local control for early stage lung cancer patients who receive SBRT

Analysis of data from an institutional patient registry on stereotactic body radiotherapy (SBRT) indicates excellent long-term, local control, 79 percent of tumors, for medically inoperable, early stage lung cancer patients treated with SBRT from 2003 to 2012, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. [More]
PORT can improve survival for non-small cell lung cancer patients

PORT can improve survival for non-small cell lung cancer patients

Patients who received post-operative radiation therapy (PORT), radiation therapy after surgery, lived an average of four months longer when compared to the patients who had the same disease site, tumor histology and treatment criteria and who did not receive PORT, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. [More]

Intrathoracic radiotherapy shows potential in extensive-stage SCLC

A phase III randomised controlled trial shows that intrathoracic radiotherapy after chemotherapy significantly reduces the chances of disease progression in patients with extensive-stage small-cell lung cancer. [More]
Concord Medical gets approval to establish Datong Meizhong Jiahe Cancer Center

Concord Medical gets approval to establish Datong Meizhong Jiahe Cancer Center

Concord Medical Services Holdings Limited, an operator of specialty cancer hospitals and the largest network of radiotherapy and diagnostic imaging centers in China, today announced that the Company has received relevant government approvals to establish a free-standing radiotherapy cancer center, Datong Meizhong Jiahe Cancer Center ("Datong Center") in Datong City, Shanxi Province. [More]